遺伝子治療:AAV遺伝子治療の長期的な安全性に懸念
Gene therapy: Concerns for the long-term safety of AAV gene therapy
doi: 10.1038/s41587-020-0741-7
doi: 10.1038/s41587-020-0741-7
doi: 10.1038/s41587-020-0684-z
Sixteen years after the commercialization of crops produced by traditional transgenic technology, a raft of new approaches are opening new opportunities in plant biotechnology. This focus issue of Nature Biotechnology highlights these technologies and their impact on plant breeding and their impact on regulatory oversight.
doi: 10.1038/nbt.2168
doi: 10.1038/nbt.2154
doi: 10.1038/nbt.2145
doi: 10.1038/nbt.2144
doi: 10.1038/nbt.2143
doi: 10.1038/nbt.2142
doi: 10.1038/nbt.2166-1
doi: 10.1038/nbt.2166-2
doi: 10.1038/nbt.2169
doi: 10.1038/nbt.2156
doi: 10.1038/nbt.2139
doi: 10.1038/nbt.2138
doi: 10.1038/nbt.2146
doi: 10.1038/nbt.2148
doi: 10.1038/nbt.2141
doi: 10.1038/nbt.2135
doi: 10.1038/nbt.2122
doi: 10.1038/nbt.2136
doi: 10.1038/nbt.2137
doi: 10.1038/nbt.2121